Renin-angiotensin-aldosterone system in the elderly: rational use of aliskiren in managing hypertension

Karl Andersen
Department of Medicine, Division of Cardiology, Landspitali University Hospital, University of Iceland, Reykjavik, Iceland

Abstract: The overall purpose of hypertension treatment is 2-fold. First, patients often have symptoms that are related to their high blood pressure and although subtle in many instances may be improved dramatically by blood pressure control. The main reason for blood pressure treatment, however, is to reduce the burden of cardiovascular complications and end organ damage related to the condition. This may be considered the ultimate goal of blood pressure treatment. In this respect, actual blood pressure measurements may be seen as surrogate endpoints as the organ protective effects of two antihypertensive agents may differ significantly even though their blood pressure lowering effects are similar. Thus beta-blockers, once seen as first-line treatment of hypertension for most patients, now are considered as third- or fourth-line agents according to the latest NICE guidelines (National Institute for Health and Clinical Excellence, www.nice.org.uk/CG034). On the other hand, agents that inhibit the activity of the renin-angiotensin-aldosterone system (RAAS) system are being established as safe, effective and end organ protective in numerous clinical trials, resulting in their general acceptance as first-line treatment in most patients with stage 2 hypertension. This shift in emphasis from beta-blockers and thiazide diuretics is supported by numerous clinical trials and has proven safe and well tolerated by patients. The impact of this paradigm shift will have to be established in future long-term randomized clinical trials. The optimal combination treatment with respect to end organ protection has yet to be determined. Most combinations will include either a RAAS active agent and calcium channel blocker or two separate RAAS active agents working at different levels of the cascade. In this respect direct renin inhibitors and angiotensin receptor blockers seem particularly promising but the concept awaits evaluation in upcoming randomized clinical trials. Although safety data from the randomized clinical trials to date have been promising, we still lack data on the long-term effect of aliskiren on mortality and there still are patient groups where the safety of aliskiren is unexplored.

Keywords: aliskiren, elderly, hypertension, renin-angiotensin-aldosterone system

Introduction
High blood pressure is a major risk factor for stroke, myocardial infarction, heart failure, peripheral artery disease and renal failure. The global prevalence of hypertension is believed to be 25% to 30% in the adult population and is steadily increasing in western societies. Among the elderly (>65 years) the prevalence of hypertension is even higher, reaching 50% to 70% and is an increasing public health concern. The condition confers a 3- to 4-fold increased risk of cardiovascular disease and renal failure and is associated with declining cognitive function among the affected.

There is a continuous independent relationship between elevated systolic blood pressure (SBP) and diastolic blood pressure (DBP) and stroke and cardiovascular mortality for all age groups. The mortality risk is doubled for every 20 mmHg rise in SBP and 10 mmHg rise in DBP from the level of 115/75 mmHg.
steadily increasing proportion of elderly in the population, it can be predicted that cardiovascular and renal complications of high blood pressure will increase even further in the coming decades unless appropriate preventive measures are taken.

In an attempt to attenuate the dire complications of hypertension, clinicians are faced with an array of antihypertensive agents. In many instances, the older generic drugs have been found as effective for blood pressure lowering as the newly developed antihypertensive agents. However, only recently randomized clinical trials have provided insight into the relative efficacy of these agents to confer end organ protection which may be seen as the ultimate goal of blood pressure treatment. Selection of antihypertensive treatment needs to be based on the presumed clinical benefit that may be obtained for different patient groups. In this context health care providers will increasingly rely on randomized clinical trials to tailor treatment alternatives to each individual patient. This review will focus on treatment of hypertension in the elderly population with special reference to the value of agents acting on the renin-angiotensin-aldosterone system (RAAS) including the direct renin inhibitor (DRI) aliskiren.

Hypertension in the elderly

With advancing age the aorta and medium size arterioles become calcified and lose elasticity. This process is dependent on age-related changes of elastin fibres in the media, proliferation of collagen and deposition of calcium. The resulting arteriosclerosis causes a rise in peripheral vascular resistance and elevated SBP but also a fall in DBP and consequently a high pulse pressure. The changes in the vascular tree that occur with advancing age are rather complicated and include, apart from calcification, humoral changes and vascular hypertrophy. This results in a continuous rise in SBP throughout adult life, whereas DBP peaks at about 60 years of age and declines thereafter. The resulting rise in pulse pressure with advancing age has been used as a predictor of adverse cardiovascular outcome.\(^{11,12}\)

Aortic stiffness, measured by carotid-femoral pulse wave velocity, increases the risk of cardiovascular mortality, coronary events and fatal strokes among the elderly.\(^{13,14}\) This risk factor becomes more important in patients over 50 years of age.\(^{11}\) The proportion of elderly subjects is steadily growing in industrialized countries and is expected to reach a quarter of the US population by year 2035.\(^{15}\) The prevalence of isolated systolic hypertension in this age group is over 65% and the lifetime risk of developing hypertension exceeds 90%. The importance of blood pressure control in this age group has been confirmed by several interventional trials.\(^{17-19}\) In spite of these facts, only 20% of elderly hypertensives have blood pressure controlled to values below 140/90 mmHg.

This may have a serious impact in the overall health of elderly people causing cardiovascular disease, heart failure, stroke, renal failure and reduced quality of life.

The RAAS in hypertension

The RAAS plays a central role in the regulation of blood pressure (Figure 1). Renin, an aspartic protease, is generated and released by the juxtaglomerular cells in the kidney. It has one known substrate, angiotensigen, and catalyzes the conversion of angiotensigen to angiotensin I (Ang I) in the rate limiting step of the cascade. Formation of Ang I is favored by a 5000-fold concentration gradient. The decapetide Ang I is then converted to the octapeptide angiotensin II (Ang II) by angiotensin-converting enzyme (ACE). The Ang II thus formed acts on receptors of Ang II (AT-1 receptors) to raise blood pressure through several mechanisms. Most importantly, Ang II is a powerful vasoconstrictor, it stimulates the release of aldosterone from the adrenal cortex and subsequently leads to sodium reabsorption in the kidney and catecholamine release from the adrenal medulla. Hypertension can be caused by pathologic activation of the RAAS, leading to salt and water reabsorption, vasoconstriction and increased catecholamine release.

Recently, the discovery of the (pro)renin receptor has changed our understanding of how the RAAS system is involved in end organ damage.\(^{20}\) Pro-renin is a precursor to renin which has a 43 amino acid N-terminus overlying the enzymatic cleft of the renin molecule, thus rendering it inactive. Pro-renin is much more abundant than renin in the circulation and its concentration is especially high in diabetics. Pro-renin can be activated both by proteolytic and non-proteolytic pathways. The proteolytic pathway takes place in the juxtaglomerular apparatus in the kidney where the 43 amino acid N-terminus is removed and leaves the active renin molecule. Non-proteolytic activation of pro-renin takes place by binding to the (pro)renin receptor. Pro-renin thereby becomes enzymatically active without losing its N-terminus and this binding increases its enzymatic activity 4 to 5-fold. The activation of pro-renin leads to Ang II production locally at the cell surface where it is in close vicinity with ACE and the AT-1 receptor. At the tissue level renin and pro-renin also have physiologic effects through the (pro)renin receptor that are completely independent of Ang II production. Intracellular signaling pathways cause upregulation of pro-fibrotic mediators that lead to contractility disturbances, hypertrophy,
fibrosis and apoptosis. This is a potential second target for control of the RAAS with renin inhibitors that might lead to organ protection beyond the blood pressure lowering effects achieved by ACE-inhibitors (ACE-I) and angiotensin receptor blockers (ARBs).

Inhibition of the RAAS has long been the target of pharmacological blood pressure regulation. Inhibitors of the ACE reduce the production of Ang II and have been proven to be effective blood pressure lowering agents. Their effectiveness is, however, hampered by the ACE-independent pathways of chymases and dipeptidases that are found in end organs such as the heart, blood vessels and kidneys. Thus, Ang II can still be produced by these pathways in spite of effective ACE-I. In addition, ACE-I often have side affects including cough that is thought to result from the accumulation of bradykinin and substance P due to the blockage of their breakdown.

Another target of RAAS inhibition is blockade of the AT-1 receptor by ARBs. Other receptors of Ang II such as AT-2 and AT-4 are not affected, but the clinical effect of their unopposed stimulation is not fully understood. This may include inflammatory and fibrotic responses leading to vascular damage and left ventricular hypertrophy. Both ACE-I and ARBs attenuate the negative feedback loop of Ang II on renin production and thus increase both renin concentration and plasma renin activity.

Direct renin inhibition (DRI) is a new concept in the treatment of hypertension.21 The prototype compound aliskiren is a small-molecular-weight, orally active, non-peptide that has high affinity for the active site on the renin molecule. Although the bioavailability of aliskiren is rather low after oral administration (2.5%), its high affinity and specificity for the renin molecule and plasma half-life of 24 to 36 hours makes it suitable for once-daily dosage. Similar to other blockers of the RAAS and thiazide diuretics, aliskiren increases plasma renin concentration (PRC). However, in contrast to other drug classes acting on the RAAS, the plasma renin activity (PRA) is effectively blocked by aliskiren. The potential benefit of DRI on end organ protection might also be related to Ang II independent effects of renin on the tissue level. Thus DRIs might not only inhibit the conversion of angiotensin to Ang I, both in the circulation and tissue level, but also blunt intracellular pathways of end organ damage induced directly by receptor bound (pro)renin.22

**Treatment of hypertension in the elderly**

Although previously thought to be of limited value or even harmful, it has now become evident from several randomized clinical trials and meta-analyses that treatment of hypertension in the elderly may reduce stroke and heart failure rates and even have a mortality effect.23,24

---

**Figure 1** The renin-angiotensin-aldosterone system and points of pharmacological intervention.

**Abbreviations:** ACE, angiotensin converting enzyme; Ang I, angiotensin I; Ang II, angiotensin II; ARB, angiotensin receptor blocker; AT1, angiotensin type I receptor.
goal of hypertension treatment is to reduce or prevent cardiovascular and renal disease. There is especially high risk for such complications in the elderly population. The increased risk of debilitating stroke caused by high SBP is a major concern among elderly hypertensives and needs to be treated aggressively, as stroke has a major impact on quality of life and life expectancy of these patients.25–27 According to current ESH-ESC Guidelines on management of hypertension28 and several clinical trials, elderly patients benefit from antihypertensive therapy in terms of reduced cardiovascular morbidity18,29–32 and mortality.24

Although elevated blood pressure has been the subject of intensive clinical and experimental studies through the last 5 decades and an arsenal of effective and safe antihypertensive medication is available, we still are far from achieving acceptable control rates. The results of the Euroaspiire III study presented at the European Congress of Cardiology in Munich 200813 showed that in spite of increased use of antihypertensive medication, the control rate of hypertension had not improved and 61% of patients were above the therapeutic target of 140/90 mmHg.

Non-pharmacological treatment
Life style modification with weight loss and reduced salt intake are of particular value in the elderly because most of these patients are obese and salt sensitive. In the Trial of Nonpharmacologic Interventions in the Elderly (TONE), sodium intake was reduced to 80 mmol (2 g) per day and resulted in a modest reduction in SBP and DBP and 40% of the treated patients were able to discontinue previous medication.34 In this study, additional blood pressure lowering was seen when weight loss was added to salt restriction. Life style modification in the elderly should also encourage physical activity.

Pharmacological treatment
Pharmacological treatment of hypertension in the elderly follows the same general principles that are laid out in the current guidelines6,22 and taking into consideration individual compelling indications for specific drug classes.35–39 However, in the elderly population these recommendations are based on a limited number of clinical trials. Bearing in mind the increased variability in blood pressure among elderly hypertensives, their reduced cardiovascular sensitivity to catecholamine stimulation and tendency to postural hypotension, care should be taken to initiate drug therapy with low doses and titrate up to effective doses according to individual response. As with hypertension in general, the elderly are likely to need two or more different medications in order to control their blood pressure.

Although it is no longer disputed that effective blood pressure treatment leads to considerable reduction in cardiovascular disease in general and stroke risk in particular, there is still uncertainty of whether specific classes of blood pressure lowering agents confer a greater benefit than others in end organ protection.40

Placebo-controlled trials
In the Swedish Trial in Old Patients with Hypertension29 1627 hypertensive patients 70 to 84 years of age were randomized in a double blind fashion to treatment with beta-blockers or thiazide diuretic vs placebo. The entry blood pressure criteria were SBP between 180 and 230 mmHg with a diastolic pressure of at least 90 mmHg, or a DBP between 105 and 120 mmHg irrespective of the systolic pressure. The mean difference in blood pressure levels between treatment arms was 19.5/8.1 mmHg after an average of 25 months of treatment. In this trial the SBP lowering effect of the thiazide was more pronounced than that of the beta-blockers. The primary end point of stroke, myocardial infarction and cardiovascular death was significantly reduced by 38% (p = 0.0031), stroke rate was reduced by 45% (p = 0.0081) and there was also a significant reduction in death rate among the actively treated patients. This study established that morbidity and mortality reductions can be achieved in elderly hypertensives with active blood pressure lowering treatment based on beta-blockers or thiazide diuretics.

The European Working Party on High Blood Pressure in the Elderly trial41 was a double-blind, placebo controlled trial of diuretic based (hydrochlorothiazide + triamterene) treatment vs placebo in hypertensive subjects, 60 years or older with entry blood pressure levels of 160 to 239 mmHg systolic and 90 to 119 mmHg diastolic. Methyldopa could be added to the active treatment group in case of suboptimal blood pressure control. The results showed no significant reduction in total mortality by active treatment (9%, p = 0.41), but a significant reduction in cardiovascular mortality (27%, p = 0.037) that was mainly driven by a 38% reduction in cardiac mortality (p = 0.036).

The Systolic Hypertension in the Elderly Program (SHEP)39 was a clinical trial where 4736 elderly subjects with stage 2 isolated systolic hypertension (systolic ≥ 160 mmHg, diastolic < 90 mmHg) were randomized to treatment with a thiazide type diuretic (chlorothalidone) or placebo. In the active treatment arm atenolol, reserpine and hydralazine could be added to achieve blood pressure control. SBP was
lower in the treatment group (143 mmHg) than the control group (155 mmHg) and the primary end point of stroke was significantly reduced by 36% (p = 0.0003), heart failure by 49% and coronary events by 27%. The treatment was well tolerated. This was a landmark trial that showed that blood pressure lowering in elderly patients was not only safe, but also effective in reducing clinical end points.

The placebo-controlled randomized HYVET trial studied 3845 hypertensive subjects over 80 years of age with a sustained SBP of 160 mmHg or greater. Treatment was initiated with a thiazide (indapamide sustained release 1.5 mg/day) and an ACE-I (perindopril 2–4 mg/day) added if needed for blood pressure control (<150/80 mmHg). The primary end point was fatal and non-fatal stroke with a median follow-up period of 1.8 years. The study was stopped prematurely by the data safety monitoring board for ethical reasons. The results showed a 30% reduction in the primary end point that was of borderline statistical significance (p = 0.06). However, there was a convincing 39% reduction in stroke mortality (p = 0.05), a 21% reduction in all cause mortality (p = 0.02) and a 64% reduction in heart failure (p < 0.001) at follow-up indicating that this approach to treat hypertensive patients 80 years or older with a thiazide diuretic, allowing optional combination with an ACE-I is not only safe, but also lowers stroke rate, heart failure and all cause mortality and thus confers a significant clinical benefit to this patient group.

These placebo-controlled trials confirm the efficacy of thiazides alone or in combinations for end organ protection in elderly hypertensives. This is supported by a meta-analysis looking at 18 placebo controlled trials of elderly hypertensive patients where diuretics were found to reduce stroke risk by 51% (relative risk [RR] 0.49, 95% confidence interval CI 0.39–0.62) and beta-blockers by 29% (RR 0.71, 95% CI 0.59–0.86) compared to placebo.

The Systolic Hypertension in Europe (Syst-Eur) study, elderly patients with systolic hypertension ≥ 160 mmHg, but diastolic <95 mmHg, were randomized to the dihydropyridine calcium channel blocker nitrindipine or placebo. The study was stopped prematurely by the data safety monitoring board because of a highly significant (p = 0.003) 43% reduction in stroke by the calcium channel blocker. More surprisingly, there was also a highly significant 55% reduction in dementia by the calcium channel blocker.

A large Chinese study of hypertensive patients 60 years or older compared the dihydropyridine calcium channel blocker nitrindipine 10 to 40 mg/day, with addition of the ACE-I captopril 12.5 to 50 mg/day or hydrochlorothiazide 12.5 to 50 mg/day for adequate blood pressure control against placebo. After 2 years of follow-up the blood pressure difference between placebo and active treatment groups was 9.1/3.2 mmHg which resulted in a significant reduction in stroke rate (38%, p = 0.01), all cause mortality (39%, p = 0.003), cardiovascular mortality (39%, p = 0.03), stroke mortality (58%, p = 0.02) and all cardiovascular end points (37%, p = 0.004) in the active treatment group as compared to placebo.

The Study on Cognition and Prognosis in the Elderly (SCOPE) was a randomized, study including 4964 patients 70 to 89 years of age with stage 2 hypertension (systolic 160–179 mmHg and or diastolic 90–99 mmHg) and a Mini Mental State Examination (MMSE) score of 24 or higher. Patients were randomized to receive the angiotensin receptor blocker candesartan or placebo with open label antihypertensive treatment added as needed for blood pressure control. After a mean follow-up of 3.7 years the primary composite end point of cardiovascular death, non-fatal stroke, and non-fatal myocardial infarction was not significantly different between treatment groups. However, non-fatal stroke was reduced by 27.8% (p = 0.04) in the candesartan group and similarly, all cause stroke was reduced by 23.6% (p = 0.056). No difference was found between groups in myocardial infarction and cardiovascular mortality. There was no difference between treatment groups in the outcome of MMSE. Blood pressure was 3.2/1.6 mmHg lower in the candesartan group.

A remarkably high rate of blood pressure control was achieved in a randomized, placebo controlled trial using perindopril 2 mg combined with indapamide 0.625 mg as active treatment during 1 year among elderly patients with essential or isolated systolic hypertension. The mean blood pressure reduction was 23/13.3 mmHg and 79.8% of the patients achieved blood pressure control with this low dose combination treatment, which was well tolerated and equally effective in elderly (65–74 years) as in very elderly (75–85 years) patients.

These placebo-controlled trials of elderly patients with stage 2 and 3 hypertension confirm that treatment of high blood pressure confers a clear benefit in reducing cardiovascular mortality and morbidity in this age group. The agents most effective in this respect seem to be thiazide diuretics, calcium channel blockers and possibly ACE-I and ARBs although the data available for the last two classes are limited.

Active comparator trials
The Swedish Trial in Old Patients with Hypertension-2 (STOP-2) study aimed to compare the effects of conventional
and newer antihypertensive drugs on cardiovascular mortality and morbidity in elderly patients. This was a prospective, randomized trial including 6614 patients, 70 to 84 years of age with SBP ≥ 180 mmHg and/or DBP ≥ 105 mmHg. The treatment in the conventional group was made up of beta-blockers (atenolol 50 mg, metoprolol 100 mg, pindolol 5 mg) or the diuretic combination of hydrochlorothiazide/amilorid 25/2.5 mg) given in a single daily dose. The newer drugs group was treated with an ACE-I (enalapril 10 mg or lisinopril 10 mg) or a dihydropyridine calcium channel blocker (felodipine 2.5 mg or isradipine 2–5 mg) daily. Importantly, blood pressure was reduced similarly in both treatment groups, so that comparison of end points between treatment arms reflects the net clinical benefit of each drug over and above blood pressure lowering efficacy. The primary end point was a composite of fatal stroke, fatal myocardial infarction and other fatal cardiovascular disease and occurred in almost exactly the same proportion (19.8 events/1000 patient years) in both treatment arms (RR 0.99, p = 0.89). The conclusion of this trial was that the older and newer antihypertensive drugs tested in this trial showed similar efficacy in preventing cardiovascular mortality and major events and therefore, the main importance for the prevention of such events would lie in the blood pressure lowering of these drugs rather than in the mechanism of action.

In a randomized study, the clinical efficacy and tolerability of irbesartan 150 to 300 mg was compared to that of enalapril 10 to 20 mg among elderly patients with mild to moderate hypertension. Both agents were well tolerated, the only significant difference being more frequent cough in the enalapril group. However, there was no difference in efficacy between the two agents compared. Although not primarily studies of elderly subjects, the patients included in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack (ALLHAT) trial, the Nordic Diltiazem study (NORDIL), Valsartan Antihypertension Long-Term Use (VALUE) and Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) (ASCOT) trials had mean ages > 65 years of age.

The ALLHAT patients had a mean age of 67 years. This was a randomized clinical trial comparing chlorthalidone, the dihydropyridine calcium channel blocker amlodipine and the ACE-I lisinopril as first-line therapy in hypertension. Add on of clonidine and reserpine was allowed for those who did not reach treatment target. All medications reduced prespecified end points of cardiovascular disease similarly with the exception that heart failure rates were about 40% higher in the amlodipine group than for chlorthalidone. In a prespecified subgroup of patients aged 65 years or older, combined coronary heart disease, combined cardiovascular disease and heart failure rates were significantly higher with lisinopril than with chlorthalidone. Combined cardiovascular disease and stroke rates were also significantly lower among patients receiving amlodipine compared with lisinopril in an elderly subpopulation of the ALLHAT study. There were no major differences in outcome in the elderly subgroup compared to the overall study population.

A subanalysis of the NORDIL study addressed the effect of age, sex, severity of hypertension and heart rate on outcome in a prospective, randomized, open label, blinded end point designed (PROBE) trial comparing the calcium channel blocker diltiazem with diuretic/beta-blocker based treatment. SBP was reduced more effectively in the diuretic/beta-blocker group, a difference of 3 mmHg (p < 0.001). The primary composite end point of cardiovascular death, cerebral stroke and myocardial infarction was nevertheless similar for both treatment arms. However, fatal and non-fatal stroke was reduced by 20% (p = 0.04) in the diltiazem group with a non-significant trend towards an increase in the rate of myocardial infarction. These results were more pronounced in the subgroup of patients with baseline SBP > 170 mmHg, DBP of 105 mmHg or higher and pulse pressure over 65 mmHg. The favorable effect of the calcium channel blocker was present across all subgroups when analyzed according to age, sex, severity of hypertension and heart rate.

The ALLHAT and NORDIL studies therefore indicate that thiazide diuretics and calcium channel blockers might be more effective in stroke prevention than are ACE-I and beta-blockers. This is supported by a meta-analysis by Lindholm et al who found that the risk of stroke was 16% higher with beta-blockers than with other antihypertensive agents.

The VALUE trial set out to evaluate for the first time by head-to-head comparison whether treatment with an ARB (valsartan) would reduce cardiac-related morbidity and mortality when compared with similar blood pressure control with the dihydropyridine calcium channel blocker amlodipine. The focus of this trial was on cardiac events, and to be eligible, patients had to have either coronary artery disease or be of considerable risk thereof. Effects on stroke rate were secondary end points in this study. As it turned out the mean age of the included patients was 67.2 years and 92% had previously treated hypertension. The mean blood pressure level at study entry was 155/92 mmHg. At the time of the study, amlodipine was a much more frequently prescribed...
drug than was valsartan. Consequently, a larger proportion of patients randomized to the amlodipine arm continued the medication they had been taking prior to study enrolment than patients randomized to the valsartan arm, most of which were taking the ARB for the first time after being previously treated with another antihypertensive agent. This difference between treatment groups probably lead to a very important result of the VALUE trial, that the achieved blood pressure in the amlodipine group was on average 4.3 mmHg lower than in the valsartan group in the early months, a difference that was still 2.2 mmHg at the end of the 5 year follow-up period. The study was therefore flawed and it is difficult to draw definitive conclusions from the main results of the trial which were that there was no difference between treatment groups in the rate of the primary end point (myocardial infarction, aborted myocardial infarction or hospitalization for congestive heart failure).

A similar problem arose in the ASCOT-BPLA.51 This was a trial aiming at answering the question whether newer antihypertensive agents (amlodipine 5–10 mg with optional addition of the ACE-I perindopril 4–8 mg) were superior to conventional first-line treatment (atenolol with optional addition of the thiazide diuretic bendroflumethiazide 1.25–2.5 mg). This was a randomized double blind, trial that enrolled over 19,000 hypertensive patients with at least 3 other cardiovascular risk factors. There was no difference between treatment groups in the primary outcome of non-fatal myocardial infarction and fatal coronary heart disease. However, there was a significant 23% relative reduction in the rate of fatal and nonfatal stroke in the amlodipine-based group (p = 0.0003) and a significant reduction of both all cause (p < 0.05) and cardiovascular mortality (p = 0.001) when the study was stopped prematurely by the data safety monitoring board after 5.5 years of follow-up. Much the same as in the VALUE trial, there was a significant imbalance between treatment groups that was 2.7/1.9 mmHg in favor of the amlodipine based regimen (p < 0.0001). Nevertheless, the authors conclude that the ASCOT trial supports the use of newer drugs, in multi-drug combinations, to modify risk factors and/or metabolic disturbances, especially in patients with complicated hypertension.

A more definitive conclusion can though be drawn from the results of the Losartan Intervention for Endpoint Reduction (LIFE) study.55 This was the first trial comparing two active antihypertensive medications to show a clear effect of one treatment arm in reducing cardiovascular events. The trial included patients with hypertension and left ventricular hypertrophy comparing the ARB losartan with the beta-blocker atenolol. Hydrochlorothiazide was added to both arms to reach treatment goals. Losartan treatment resulted in a 25% relative reduction in stroke compared with atenolol. In a substudy of patients with isolated systolic hypertension56 1326 patients with SBP 160 to 200 mmHg and DBP of less than 90 mmHg were recruited. The mean blood pressure at randomization was 174/83 mmHg and the mean age of the patients was 70 years. The primary end point was a composite of cardiovascular death, stroke or myocardial infarction. After a mean follow-up period of 4.7 years the primary end point was reduced by 25% by losartan treatment compared with atenolol (p = 0.06). After adjustment for risk and degree of left ventricular hypertrophy the relative risk reduction was 29% (p = 0.02). There was a significant reduction in cardiovascular mortality (46%, p = 0.01), non-fatal and fatal stroke (40%, p = 0.02), new onset diabetes (38%, p = 0.04) and total mortality (38%, p = 0.046). Importantly, there was no significant difference between treatment groups in blood pressure throughout the study. The LIFE study is thus a landmark trial indicating that high risk hypertensive and predominantly elderly patients (with or without isolated systolic hypertension) have a mortality and morbidity benefit from treatment with losartan compared to atenolol.

These results have strongly influenced current international guidelines in that beta-blockers are no longer regarded as first line treatment of hypertension unless compelling indication and co-morbidities dictate otherwise. The LIFE study is also remarkable for the fact that the ARB losartan seems to reduce the risk of stroke more than does atenolol and it was the first trial to indicate that ARBs are in addition to calcium antagonists first-line drugs in stroke prevention for patients with hypertension.

The same conclusion was drawn from the Blood Pressure Lowering Trialists’ Collaboration analysis57 and the JIKEI Heart Study58 that both confirmed the organ protective effects of ARBs.

The majority of patients with type 2 hypertension will need combination treatment to reach treatment targets. Current guidelines6–28 dictate the use of combinations as first-line treatment in these patients, of which one should be a thiazide diuretic. These recommendations are challenged by the recently published ACCOMPLISH trial results.59 The main objective of this study was to compare the effect of two combination therapies on clinical end points among high risk patients with hypertension. These were 11,506 patients 55 years and older with SBP 160 mmHg or higher. All had a history of hypertension treatment and were of high risk. The combinations tested were benazepril/amlodipine
against benazepril/hydrochlorothiazide. The data safety monitoring board stopped the trial early because of a 20% (p < 0.001) lower rate of major adverse cardiac events in the benazepril/amlodipine combination compared to benazepril/hydrochlorothiazide.

Taken together, the evidence from randomized clinical trials to date confirm that effective blood pressure control and end organ protection can be achieved by any of the following classes of antihypertensive agents; thiazide diuretics, beta-blockers, calcium channel antagonists, ACE-I and ARBs. Until recently however, clinicians have had little data to compare the relative efficacy of these agents either as monotherapy or in various combinations. The mounting evidence now available challenges previous and current guidelines in that optimal clinical results seem to be obtainable by agents that block the RAAS system at different levels in combination with calcium channel blockers rather than with thiazide diuretics or beta-blockers. Within the RAAS cascade, combination therapy is also an attractive alternative.

Renin inhibition

In preclinical studies, the DRI aliskiren has been shown to have organ protective effects.\textsuperscript{60-63} Recent clinical end point trials indicate that aliskiren might also have end organ protective effects similar to ACE-I and ARBs in high risk patients.

Several placebo-controlled trials have assessed the antihypertensive effects of aliskiren.\textsuperscript{59,64-68} In these trials, aliskiren was found to be both effective and well tolerated. The blood pressure lowering effect in these trials was comparable or greater than those seen in other trials of hydrochlorothiazides, irbesartan and amlodipine. The results of major clinical trials of aliskiren are summarized in Table 1.

A few studies have compared the blood pressure lowering effect of aliskiren with other antihypertensive agents.\textsuperscript{68-74} Pool et al\textsuperscript{59} investigated the blood pressure lowering effect of aliskiren alone or in combination with valsartan in a randomized clinical trial including 1123 patients with mild to moderate hypertension (msDBP \(\geq 95\) mmHg). They found both aliskiren and valsartan to produce dose-related reduction in both systolic and DBP in doses ranging from 75 to 300 mg and 80 to 320 mg respectively. The co-administration of aliskiren and valsartan produced a greater antihypertensive effect than either agent alone and comparable to valsartan/hydrochlorothiazide, with similar tolerability compared to the component monotherapies and to placebo.

Oparil et al conducted a randomized clinical trial\textsuperscript{71} of 1797 hypertensive patients (msDBP 95–109 mmHg) treated with either aliskiren 150 mg od, valsartan 160 mg od, a combination of the two or placebo for 4 weeks. Thereafter, forced titration was made to the double doses for another 4 weeks. The combination of aliskiren/valsartan 300/320 mg lowered the mean seated DBP from baseline by 12.2 mmHg, that was significantly more than for placebo or either monotherapy (9.0 and 9.7 mmHg for aliskiren and valsartan respectively, p < 0.0001). The aliskiren/valsartan combination also lowered mean seated SBP (msSBP) significantly by 17.2 mmHg as compared to aliskiren (13.0 mmHg) and valsartan (12.8 mmHg) treatment respectively, p < 0.0001). Rates of adverse events were similar in all groups.

Dahlöf et al\textsuperscript{75} performed a meta-analysis of 8481 patients included in placebo controlled trials with aliskiren as active treatment. The blood pressure lowering effects of aliskiren 150 and 300 mg od were 12.5/10.1 and 15.2/11.8 mmHg respectively from baseline compared to 6.2/5.9 mmHg for placebo (p < 0.0001).

In a study of obese hypertensive patients (ms DBP 95–109 mmHg, body mass index 30 kg/m\textsuperscript{2} or higher), not responsive to hydrochlorothiazide monotherapy,\textsuperscript{70} Jordan et al compared the effect of aliskiren, irbesartan, amlodipine or placebo as add on treatment in conventional doses. After 8 weeks of treatment the aliskiren/hydrochlorothiazide 300/25 mg combination resulted in a 15.8/11.9 mmHg lowering of blood pressure that was similar to those obtained by irbesartan/hydrochlorothiazide 300/25 mg and amlodipine/hydrochlorothiazide 10/25 mg. The tolerability of aliskiren/hydrochlorothiazide was similar to that of placebo/hydrochlorothiazide.

In a dose escalating study, Stanton et al\textsuperscript{72} compared the effects of aliskiren (37.5–300 mg od) to that of losartan 100 mg in 226 patients with mild to moderate hypertension (mean daytime ambulatory SBP \(\geq 140\) mmHg) during 4 weeks of treatment. Dose-dependent reductions were seen in systolic ambulatory blood pressure and plasma renin activity, but the blood pressure lowering effects of aliskiren (75–300 mg) were not significantly different from those of losartan 100 mg.

The antihypertensive effect and safety of aliskiren 150 to 300 mg was compared to that of ramipril 5 to 10 mg both as monotherapy and combination of the two in a randomized trial of 837 diabetic patients with hypertension (msDBP 96–109 mmHg).\textsuperscript{73} Aliskiren was well tolerated either as monotherapy or combination with ramipril. After 8 weeks of treatment the patients receiving combination treatment had 4.6/2.1 mmHg lower mean blood pressure than either monotherapy.
A randomized study compared the efficacy and tolerability of aliskiren-based therapy with ramipril-based therapy among 846 hypertensive patients (msDBP 95–109 mmHg) during 6 months of treatment. Aliskiren was given 150 to 300 mg with ramipril 5 to 10 mg as an active comparator. Hydrochlorothiazide 12.5 to 25 mg was added in each arm in case of inadequate blood pressure control. Aliskiren provided significantly better blood pressure reduction (msSBP 17.9 vs 15.2 mmHg, p = 0.0036, mDBP 13.2 vs 12.0 mmHg, p = 0.025) and resulted in higher rates of blood pressure control (61.4% vs 53.0%, p = 0.0205).

Similar results were seen in a trial comparing aliskiren 150 mg with atenolol 50 mg. After 12 weeks of treatment the blood pressure lowering effects of both agents were similar (14.3/11.3 vs 14.3/11.7 mmHg respectively) although the combination of both was more effective than either monotherapy (17.3/14.1 mmHg).

These studies confirm that aliskiren, either alone or in several combinations, is well tolerated and has blood pressure lowering effects similar to the diverse comparators. However, these trials did not focus on end organ protection and typically included patients 50–55 years of age.

End organ protection with aliskiren

In the AVOID trial 599 patients with type 2 diabetes mellitus and hypertension with nephropathy, were studied in a double blind randomized trial. They were optimally treated with antihypertensive medication including losartan 100 mg od and received in addition aliskiren vs placebo. At baseline, the mean seated blood pressure was relatively well controlled (135/78 mmHg). The primary end point was decrease in urinary albumin to creatinin ratio (UACR) after 6 months of treatment. The primary end point was reduced by 20% (p < 0.001) in the aliskiren group as compared to placebo and reduction of more than 50% in UACR was seen significantly more often in the aliskiren group (24.7%) than in the placebo group (12.5%). This antiproteinuric effect was reached in the aliskiren-treated patients although the reductions in mean SBP (2 mmHg, p = 0.07) and DBP (1 mmHg, p = 0.08) were only marginal. It was concluded that aliskiren might have renoprotective effects that were independent of its blood pressure lowering effects in patients with diabetes and hypertension with nephropathy who are receiving recommended renoprotective treatment.

The Aliskiren Observation of Heart Failure Treatment (ALOFT) investigators studied the effects of adding aliskiren to an ACE-I in patients with heart failure. Patients (n = 302) with New York Heart Association II–IV heart failure and current or past history of hypertension were included in a randomized double blind trial. Three months treatment of aliskiren 150 mg or placebo was added to a previous regimen of ACE-I (or ARB) and beta-blocker. The mean age of the patients was 68 years and their mean left ventricular ejection fraction was 31%. The mean seated blood pressure at study entry was 129/77 mmHg. The systolic BP did not change significantly between treatment groups, but there was a marginal effect of msDBP lowering (2.9 vs 0.2 mmHg, p = 0.06) for aliskiren vs placebo respectively. The mean N-terminal pro-BNP level was approximately 2100 pg/mL at baseline. The plasma N-terminal pro-BNP rose by 762 (±6123) pg/mL in the placebo group and fell by 244 (±2015) pg/mL in the aliskiren group after 12 weeks of treatment. Total BNP and urinary aldosterone were also reduced by aliskiren. It was concluded that addition of aliskiren to an ACE-I (or ARB) and beta-blocker had favorable neurohormonal effects in heart failure and appeared to be well tolerated.

The ALLAY study focused on the effects of aliskiren alone or in combination with losartan compared to losartan alone in the reduction of left ventricular hypertrophy among 460 overweight hypertensive patients with left ventricular hypertrophy. This study showed that aliskiren reduced left ventricular hypertrophy as effectively as losartan (–5.4% vs –4.7%, p = ns). However no effect on the primary end point was reached in this study as the combination of the two agents was not significantly more effective than each monotherapy alone in reducing left ventricular hypertrophy. The decrease in left ventricular hypertrophy turned out to be directly related to the level of blood pressure reduction achieved. However, at baseline the blood pressure was approximately 145/89 mmHg and was similarly reduced in all treatment groups (aliskiren group by 6.5/3.8 mmHg, losartan group by 5.5/3.7 mmHg and aliskiren/valsartan combination group by 6.6/4.6 mmHg, p = ns). The lack of difference between treatment arms might be due to the fact that additional treatment was allowed to reach treatment targets in all groups.

Aliskiren and the elderly

The safety and tolerability of aliskiren was studied in 355 elderly patients (65 years or older) with systolic hypertension (msSBP 145–179 mmHg or mean ambulatory SBP 135 mmHg or higher). After 8 weeks of treatment aliskiren doses of 75, 150 and 300 mg and lisinopril 10 mg lowered mean ambulatory SBP by 8.4, 7.1, 8.7 and 10.2 mmHg respectively. Mean ambulatory DBP was lowered by 4.5; 3.6; 3.9 and 6.3 mmHg respectively. All treatment groups lowered msSBP and msDBP significantly compared to...
### Table 1 Major clinical trials of aliskiren

<table>
<thead>
<tr>
<th>Reference</th>
<th>Publication year</th>
<th>Number of patients</th>
<th>Treatment</th>
<th>Main results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gradman et al(^6^4)</td>
<td>2005</td>
<td>652</td>
<td>Aliskiren 150–600&lt;br&gt;Irbesartan 150&lt;br&gt;Placebo</td>
<td>Dose ranging study; all aliskiren doses showing significant effect on SBP and DBP compared to placebo. Plateau at 300 mg aliskiren with similar effect of aliskiren 150 mg and irbesartan 150 mg</td>
</tr>
<tr>
<td>Villamil et al(^6^5)</td>
<td>2007</td>
<td>2776</td>
<td>Aliskiren 75–300&lt;br&gt;HCTZ 6.25–25&lt;br&gt;Aliskiren/HCTZ 75–300/6.25–25</td>
<td>Dose ranging study; all aliskiren doses showing significant dose-dependent effect on DBP compared to placebo. Aliskiren 150–300 mg, all HCTZ doses and all combinations superior to placebo in SBP effect. Aliskiren lowered PRA</td>
</tr>
<tr>
<td>Oh et al(^6^6)</td>
<td>2007</td>
<td>672</td>
<td>Aliskiren 150–600&lt;br&gt;Placebo</td>
<td>Dose ranging study; all aliskiren doses showing significant dose-dependent effect on SBP and DBP compared to placebo. Aliskiren resulted in PRA reductions and increased PRC</td>
</tr>
<tr>
<td>Kushiro et al(^6^7)</td>
<td>2006</td>
<td>455</td>
<td>Aliskiren 75–300&lt;br&gt;Placebo</td>
<td>Aliskiren produced a significant and dose-dependent reduction in SBP and DBP compared to placebo. Placebo-like tolerability of aliskiren</td>
</tr>
<tr>
<td>Pool et al(^6^8)</td>
<td>2007</td>
<td>1123</td>
<td>Aliskiren 75–300&lt;br&gt;Valsartan 80–320&lt;br&gt;Aliskiren/valsartan 75–300/80–320&lt;br&gt;Valsartan/HCTZ 160/12.5&lt;br&gt;Placebo</td>
<td>Aliskiren and valsartan both produced dose-related reductions in SBP and DBP. Co-administration more effective than either monotherapy and comparative to valsartan/HCTZ. Well tolerated</td>
</tr>
<tr>
<td>Dietz(^6^9)</td>
<td>2008</td>
<td>694</td>
<td>Aliskiren 150&lt;br&gt;Atenolol 50</td>
<td>Similar blood pressure reduction with aliskiren and atenolol. Combination was more effective than either monotherapy</td>
</tr>
<tr>
<td>Jordan et al(^7^0)</td>
<td>2007</td>
<td>490</td>
<td>Aliskiren 150-valsartan/HCTZ 300/25&lt;br&gt;Irbesartan 150-irbesartan/HCTZ 300/25&lt;br&gt;Amlodipine 5-amldodipine/HCTZ 10/25&lt;br&gt;Placebo/HCTZ 25</td>
<td>BP lowering similar for aliskiren/HCTZ as for irbesartan/HCTZ and amlodipine/HCTZ. Aliskiren/HCTZ tolerated similar to placebo/HCTZ</td>
</tr>
<tr>
<td>Oparil S et al(^7^1)</td>
<td>2007</td>
<td>1797</td>
<td>Aliskiren 150–300&lt;br&gt;Valsartan 160–320&lt;br&gt;Aliskiren/valsartan 150/160–300/320&lt;br&gt;Placebo</td>
<td>Combination of aliskiren and valsartan more effective in reducing both SBP and DBP than either monotherapy alone</td>
</tr>
<tr>
<td>Stanton et al(^7^2)</td>
<td>2003</td>
<td>226</td>
<td>Aliskiren 37.5–300&lt;br&gt;Losartan 100</td>
<td>Similar dose-dependent reduction in ABPM for aliskiren and losartan</td>
</tr>
<tr>
<td>Uresin et al(^7^3)</td>
<td>2007</td>
<td>837</td>
<td>Aliskiren 150–300&lt;br&gt;Ramipril 5–10&lt;br&gt;Aliskiren/ramipril 5/150–10/300</td>
<td>Patients with diabetes. Aliskiren well tolerated either alone or in combination with ramipril. Combination treatment reduced BP 4.6/2.1 over monotherapy</td>
</tr>
<tr>
<td>Andersen et al(^7^4)</td>
<td>2008</td>
<td>842</td>
<td>Aliskiren 150–300 (HCTZ 12.5–25)&lt;br&gt;Ramipril 5–10 (HCTZ 12.5–25)</td>
<td>Aliskiren provided significantly better SBP and DBP reduction and higher rates of BP control than ramipril-based therapy</td>
</tr>
<tr>
<td>Dahlöf(^7^5)</td>
<td>2007</td>
<td>8481</td>
<td>Aliskiren 150–300&lt;br&gt;Placebo (meta-analysis)</td>
<td>Aliskiren 150 and 300 mg treatment resulted in a significant 12.5/10.1 and 15.2/11.8 mmHg lowering in BP compared to 6.2/5.9 mmHg for placebo</td>
</tr>
</tbody>
</table>

(Continued)
### Table 1 (Continued)

<table>
<thead>
<tr>
<th>Reference</th>
<th>Publication year</th>
<th>Number of patients</th>
<th>Treatment</th>
<th>Main results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parving H-H et al&lt;sup&gt;76&lt;/sup&gt;</td>
<td>2008</td>
<td>599</td>
<td>Aliskiren 150–300 Placebo</td>
<td>Pts with diabetes and nephropathy optimally treated with losartan at baseline. UACR reduced 20% by aliskiren treatment compared to placebo without significant reductions in BP. UACR reduction of 50% or more was seen twice as often in aliskiren group.</td>
</tr>
<tr>
<td>McMurray et al&lt;sup&gt;77&lt;/sup&gt;</td>
<td>ALOFT 2008</td>
<td>302</td>
<td>Aliskiren 150 Placebo</td>
<td>Pts with CHF and HT on baseline treatment with ACE-I (or ARB) and beta-blocker. Aliskiren was well tolerated and showed favorable neurohormonal effects (pro-BNP lowering).</td>
</tr>
<tr>
<td>Solomon et al&lt;sup&gt;78&lt;/sup&gt;</td>
<td>ALLAY 2008</td>
<td>460</td>
<td>Aliskiren Losartan</td>
<td>Aliskiren and losartan equally effective in reducing left ventricular hypertrophy, with no additional effect from combination therapy.</td>
</tr>
<tr>
<td>Verdecchia et al&lt;sup&gt;79&lt;/sup&gt;</td>
<td>2007</td>
<td>355</td>
<td>Aliskiren 75–300 Lisinopril 10</td>
<td>Elderly population (65 years and older) with HT. Aliskiren was well tolerated. All treatment groups lowered mean seated SBP and DBP compared to baseline.</td>
</tr>
<tr>
<td>Schmieder et al&lt;sup&gt;80&lt;/sup&gt;</td>
<td>2008</td>
<td>1124</td>
<td>Aliskiren 300 (amlodipine 5–10) HCTZ 25 (amlodipine 5–10)</td>
<td>Post-hoc analysis comparing elderly and very elderly to younger pts with HT. After 52 weeks aliskiren provided significantly greater reductions in SBP and PP among elderly and very elderly as compared to younger pts. Aliskiren was well tolerated and more effective than HCTZ.</td>
</tr>
<tr>
<td>Yarows et al&lt;sup&gt;81–82&lt;/sup&gt;</td>
<td>2008</td>
<td>1797</td>
<td>Aliskiren Valsartan</td>
<td>Subgroup analysis comparing elderly with younger patients. Aliskiren monotherapy and aliskiren/valsartan combinations were equally well tolerated in elderly as in younger pts. Combination treatment more effective than monotherapy in SBP lowering and control rates among elderly pts.</td>
</tr>
<tr>
<td>Gradman et al&lt;sup&gt;83&lt;/sup&gt;</td>
<td>2008</td>
<td>776</td>
<td>Aliskiren 150</td>
<td>Pooled analysis of 8 RCTs comparing efficacy of aliskiren among elderly vs younger pts with HT. Aliskiren 150 and 300 mg lowered BP significantly compared with placebo independent of age in pts with hypertension.</td>
</tr>
<tr>
<td>Duprez et al&lt;sup&gt;84&lt;/sup&gt;</td>
<td>AGELESS 2008</td>
<td>900</td>
<td>Aliskiren 150–300 (HCTZ 12.5–25) (amlodipine 5–10) Ramipril 5–10 (HCTZ 12.5–25) (amlodipine 5–10)</td>
<td>Dose escalating study of aliskiren-HCTZ-amlodipine vs ramipril-HCTZ-amlodipine among elderly pts with HT. Aliskiren-based therapy was superior to ramipril-based therapy at 12 weeks and non-inferior at 36 weeks in msSBP lowering. A higher control rate and less need for add-on therapy was seen for aliskiren compared with ramipril therapy.</td>
</tr>
</tbody>
</table>

**Abbreviations:** ABPM, ambulatory blood pressure monitoring; ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BNP, brain natriuretic peptide; BP, blood pressure; CHF, congestive heart failure; HCTZ, hydrochlorothiazide; HT, hypertension; DBP, diastolic blood pressure; SBP, systolic blood pressure; msSBP, mean seated systolic blood pressure; PRA, plasma renin activity; PRC, plasma renin concentration; PP, pulse pressure; RCTs, randomized clinical trials; UACR, urinary albumin to creatinine ratio.
baseline and the proportion of patients that reached blood pressure control (<140/90 mmHg) with aliskiren 300 mg was greater than with aliskiren 75 mg (36.2% vs 24.2%, p = 0.033). Importantly, there was no evidence of dose-related increases in the incidence of adverse events in this elderly population.

In a post-hoc analysis of a double blind randomized trial, Schmieder et al studied the blood pressure lowering effect of aliskiren 300 mg vs hydrochlorothiazide 25 mg in 1124 elderly (≥65 years) and very elderly (≥75 years) patients with hypertension. Amlodipine 5 to 10 mg was added as needed to reach target blood pressure of 140/90. After 52 weeks aliskiren based treatment provided significantly greater reductions in SBP and pulse pressure among the elderly and very elderly patients than in younger patients (p < 0.05). Blood pressure control rates were greater with aliskiren-based therapy than with hydrochlorothiazide therapy in the elderly and aliskiren was well tolerated. This study indicates that aliskiren is well tolerated in elderly and very elderly patients and is more effective than thiazide diuretics in lowering systolic hypertension and elevated pulse pressure.

In another subgroup analysis of a randomized double blind trial including 1797 patients with hypertension, Yarrows et al studied the effect of aliskiren, valsartan and the combination of both in elderly patients compared to those younger than 65 years of age. Aliskiren monotherapy and aliskiren/valsartan combinations were equally well tolerated in the elderly as in younger patients. The combination provided greater reductions in SBP and blood pressure control rates than did valsartan monotherapy in the elderly patients. The effect of aliskiren/valsartan and high dose valsartan on pulse pressure was greater in elderly patients than in younger patients.

In a pooled analysis of 8 randomized clinical trials of hypertensive patients (msDBP 95–109 mmHg) treated with aliskiren Gradman et al found aliskiren to provide effective blood pressure reductions and improve responder rates compared with placebo, and independent of age.

Finally, the AGELESS study, presented at the American Heart Association 2008 Scientific Sessions, was a randomized trial of hypertensive patients, 65 years of age and older. Nine hundred and one patients received either aliskiren 150 mg od or ramipril 5 mg od for 4 weeks. If the treatment goal of 140 mmHg SBP was not reached at 4 weeks, the doses were doubled. At 12 weeks, hydrochlorothiazide 12.5 to 25 mg could be added, followed by amlodipine 5 to 10 mg daily. The mean age of the study population was 72 years and 53% were females. Patients 75 years or older made up 32.5% of the population. The incidence of adverse events was similar between groups. At 12 weeks end point aliskiren treatment resulted in a significantly greater reduction of SBP than ramipril (13.6 vs 11.3 mmHg, p < 0.0001) (mean difference –2.32 mmHg, 95% CI –4.34 to 0.30, p = 0.0421). At the 36-week end point, aliskiren-based treatment was non-inferior to ramipril based treatment although the difference (–1.92, 95% CI –4.03 to 0.19, p = 0.0747) did not reach statistical significance.

In summary, renin inhibition with aliskiren has been shown to be at least equally effective for blood pressure lowering as ramipril, losartan, valsartan, lisinopril, atenolol and hydrochlorothiazide both as monotherapy and in combinations. Aliskiren has shown some organ protective effects and is well tolerated and effective in both elderly hypertensive as well as hypertensive patients in general.

**Conclusion**

High blood pressure is a major risk factor for cardiovascular and renal complications. This risk is especially well established in the elderly population. Contrary to earlier belief, a number of clinical trials have shown blood pressure treatment to be both safe and effective in end organ protection in elderly patients. Most of the elderly will need combination therapy to control their blood pressure and achieve optimal end organ protection. Recent trials indicate that agents blocking the RAAS might be more effective for this purpose through diverse pleiotropic effects. Calcium channel blockers, being both well tolerated, safe and effective for blood pressure control, remain first-line drugs in the treatment of hypertension in elderly patients, especially in combinations with inhibitors of the RAAS. Thiazide diuretics still have their place as first-line agents in blood pressure control as they are both inexpensive, effective and well tolerated. The DRI aliskiren has been shown to have at least comparable blood pressure lowering effects as other RAAS inhibitors, and a few early clinical trials indicate that it may provide a significant benefit in combination with other agents for end organ protective effects. Aliskiren has some theoretical advantages that could contribute to its end organ protection. However, upcoming randomized clinical trials will have to determine whether these effects translate into a significant clinical benefit to reduce end organ damage in the elderly population.

**Disclosures**
The author disclosures no conflicts of interest.
References


33. Wood D, on behalf of the EUROASPIRE III Investigators. Risk factor management in coronary patients-results from a European wide survey. Euroaspira III. European Society of Cardiology, 2008; Munich, Germany.


